List of Xcopri drug patents
Xcopri is owned by Sk Life.
Xcopri contains Cenobamate.
Xcopri has a total of 1 drug patent out of which 0 drug patents have expired.
Xcopri was authorised for market use on 10 March, 2020.
Xcopri is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Xcopri from March, 2024.
The generics of Xcopri are possible to be released after 30 October, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598279 | SK LIFE | Neurotherapeutic azole compounds |
Oct, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 10, 2025 |
Drugs and Companies using CENOBAMATE ingredient
NCE-1 date: March, 2024
Market Authorisation Date: 10 March, 2020
Treatment: NA
Dosage: TABLET;ORAL
XCOPRI family patents
2
Korea, Republic of
2
United States
1
Brazil
1
Australia
1
Poland
1
Malaysia
1
Netherlands
1
Spain
1
Mexico
1
Japan
1
Argentina
1
South Africa
1
Portugal
1
Russia
1
China
1
Canada
1
Taiwan, Province of China
1
Denmark
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic